In the KEYNOTE-022 phase 2 randomized trial, the combination of pembrolizumab with BRAF/MEK targeted therapy for the treatment of patients with BRAF(V600)-mutant melanoma led to substantial improvement in prognosis; however, it was also linked to a higher incidence of toxicity (68). This evidence concerns the gene MAP2K7 and melanoma.